Replication fidelity mutants as attenuated poliovirus seeds for IPV production

Investigator: Raul Andino-Pavlovsky, PhD
Sponsor: World Health Organization (WHO)

Location(s): United States


Inactivated polio vaccine (IPV) is produced from wild-type poliovirus strains of each serotype that have been inactivated with formalin. As an injectable vaccine, it can be administered alone or in combination with other vaccines (e.g., diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenza). Generally three spaced doses are administered to generate adequate levels of seroconversion, and most countries, a booster dose is added during late childhood. IPV has been used successfully in the polio eradication programs in a few countries, notably in Scandinavia and the Netherlands, but until recently most countries have used the oral polio vaccine. IPV provides serum immunity to all three types of poliovirus, resulting in protection against paralytic poliomyelitis. See WHO site

This project looks at specific mutations, and their use in polio vaccine production.